Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer

Cancer statistics, 2016

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess et al. · Journal of Clinical Oncology · 2008 · 2.9K citations · Full text

Medicine, Oncology, Breast Oncology +16

Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes

Gϋnter von Minckwitz, Michael Untch, Jens‐Uwe Blohmer et al. · Journal of Clinical Oncology · 2012 · 2.7K citations

Medicine, Oncology, Breast Oncology +15

Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype

Katrina Bauer, Monica Brown, Rosemary D. Cress et al. · Cancer · 2007 · 2.1K citations

Medicine, Oncology, Breast Oncology +11

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group

M. Dowsett, Torsten O. Nielsen, Roger A’Hern et al. · JNCI Journal of the National Cancer Institute · 2011 · 2K citations · Full text

Medicine, Cancer Biology, Oncology +8